Female Genital Tract Secretions and Semen Impact the Development of Microbicides for the Prevention of HIV and Other Sexually Transmitted Infections

Betsy Herold, Pedro M. Mesquita, Rebecca P. Madan, Marla J. Keller

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Citation Herold BC, Mesquita PM, Madan RP, Keller MJ. Female genital tract secretions and semen impact the development of microbicides for the prevention of human immunodeficiency virus (HIV) and other sexually transmitted infections. Am J Reprod Immunol 2011; 65: 325-333 Pharmacologic strategies for the prevention of HIV include vaccines, post-exposure prophylaxis with antiretroviral therapy, and topical microbicides. Vaginal microbicides have the potential to augment innate defenses in the genital tract but may also disrupt endogenous protection and increase HIV acquisition risk, as observed in clinical trials of nonoxynol-9. The initially disappointing results of microbicide clinical trials stimulated the development of more sensitive and comprehensive pre-clinical safety studies, which include dual-chamber culture systems to model the epithelial barrier and post-coital studies to evaluate the effects of semen and sexual intercourse on microbicide efficacy. This review discusses the key factors that contribute to a healthy female genital tract environment, the impact of semen on mucosal defense, and how our understanding of these mediators informs the development of effective vaginal microbicides.

Original languageEnglish (US)
Pages (from-to)325-333
Number of pages9
JournalAmerican Journal of Reproductive Immunology
Volume65
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Sexually Transmitted Diseases
Anti-Infective Agents
Semen
HIV
Nonoxynol
Post-Exposure Prophylaxis
Clinical Trials
Local Anti-Infective Agents
Coitus
Vaccines
Safety
Therapeutics

Keywords

  • Defensins
  • HIV
  • Microbicides
  • Mucosal immunity
  • Semen
  • SLPI

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

@article{dc4156f7994043ee83f3fe29c639e490,
title = "Female Genital Tract Secretions and Semen Impact the Development of Microbicides for the Prevention of HIV and Other Sexually Transmitted Infections",
abstract = "Citation Herold BC, Mesquita PM, Madan RP, Keller MJ. Female genital tract secretions and semen impact the development of microbicides for the prevention of human immunodeficiency virus (HIV) and other sexually transmitted infections. Am J Reprod Immunol 2011; 65: 325-333 Pharmacologic strategies for the prevention of HIV include vaccines, post-exposure prophylaxis with antiretroviral therapy, and topical microbicides. Vaginal microbicides have the potential to augment innate defenses in the genital tract but may also disrupt endogenous protection and increase HIV acquisition risk, as observed in clinical trials of nonoxynol-9. The initially disappointing results of microbicide clinical trials stimulated the development of more sensitive and comprehensive pre-clinical safety studies, which include dual-chamber culture systems to model the epithelial barrier and post-coital studies to evaluate the effects of semen and sexual intercourse on microbicide efficacy. This review discusses the key factors that contribute to a healthy female genital tract environment, the impact of semen on mucosal defense, and how our understanding of these mediators informs the development of effective vaginal microbicides.",
keywords = "Defensins, HIV, Microbicides, Mucosal immunity, Semen, SLPI",
author = "Betsy Herold and Mesquita, {Pedro M.} and Madan, {Rebecca P.} and Keller, {Marla J.}",
year = "2011",
month = "3",
doi = "10.1111/j.1600-0897.2010.00932.x",
language = "English (US)",
volume = "65",
pages = "325--333",
journal = "American Journal of Reproductive Immunology and Microbiology",
issn = "1046-7408",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Female Genital Tract Secretions and Semen Impact the Development of Microbicides for the Prevention of HIV and Other Sexually Transmitted Infections

AU - Herold, Betsy

AU - Mesquita, Pedro M.

AU - Madan, Rebecca P.

AU - Keller, Marla J.

PY - 2011/3

Y1 - 2011/3

N2 - Citation Herold BC, Mesquita PM, Madan RP, Keller MJ. Female genital tract secretions and semen impact the development of microbicides for the prevention of human immunodeficiency virus (HIV) and other sexually transmitted infections. Am J Reprod Immunol 2011; 65: 325-333 Pharmacologic strategies for the prevention of HIV include vaccines, post-exposure prophylaxis with antiretroviral therapy, and topical microbicides. Vaginal microbicides have the potential to augment innate defenses in the genital tract but may also disrupt endogenous protection and increase HIV acquisition risk, as observed in clinical trials of nonoxynol-9. The initially disappointing results of microbicide clinical trials stimulated the development of more sensitive and comprehensive pre-clinical safety studies, which include dual-chamber culture systems to model the epithelial barrier and post-coital studies to evaluate the effects of semen and sexual intercourse on microbicide efficacy. This review discusses the key factors that contribute to a healthy female genital tract environment, the impact of semen on mucosal defense, and how our understanding of these mediators informs the development of effective vaginal microbicides.

AB - Citation Herold BC, Mesquita PM, Madan RP, Keller MJ. Female genital tract secretions and semen impact the development of microbicides for the prevention of human immunodeficiency virus (HIV) and other sexually transmitted infections. Am J Reprod Immunol 2011; 65: 325-333 Pharmacologic strategies for the prevention of HIV include vaccines, post-exposure prophylaxis with antiretroviral therapy, and topical microbicides. Vaginal microbicides have the potential to augment innate defenses in the genital tract but may also disrupt endogenous protection and increase HIV acquisition risk, as observed in clinical trials of nonoxynol-9. The initially disappointing results of microbicide clinical trials stimulated the development of more sensitive and comprehensive pre-clinical safety studies, which include dual-chamber culture systems to model the epithelial barrier and post-coital studies to evaluate the effects of semen and sexual intercourse on microbicide efficacy. This review discusses the key factors that contribute to a healthy female genital tract environment, the impact of semen on mucosal defense, and how our understanding of these mediators informs the development of effective vaginal microbicides.

KW - Defensins

KW - HIV

KW - Microbicides

KW - Mucosal immunity

KW - Semen

KW - SLPI

UR - http://www.scopus.com/inward/record.url?scp=79551614982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551614982&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0897.2010.00932.x

DO - 10.1111/j.1600-0897.2010.00932.x

M3 - Article

C2 - 21143689

AN - SCOPUS:79551614982

VL - 65

SP - 325

EP - 333

JO - American Journal of Reproductive Immunology and Microbiology

JF - American Journal of Reproductive Immunology and Microbiology

SN - 1046-7408

IS - 3

ER -